That admission is what some in the field call recursive self-improvement (RSI), the point at which large language models ...

Targeted therapies meet AI-driven discovery as these biotech innovators reveal sharply contrasting financials, risk factors, ...

Moderna expands beyond vaccines while Recursion bets on AI-driven drug discovery, each with distinct risks, partnerships, and ...

View Recursion Pharmaceuticals, Inc. Class A RXRX stock quote prices, financial information, real-time forecasts, and company news from CNN.

Two AI-driven disruptors, one biotech-focused, one software-first, post double-digit growth but diverge sharply on risk, cash flow, and valuation.

Recursion 2026年第一季度每股收益（EPS）为-0.22美元，超出市场预期的-0.26美元；但营收表现不佳，录得647万美元，远低于市场预期的1628万美元，差距高达60.26%。 受喜忧参半的业绩和营收大幅不及预期的影响，公司股价在盘前交易中下跌1.84%，报3.20美元。 公司将现金运营支出同比削减了30%；并维持6.65亿美元的现金头寸，这将公司财务跑道延长至2028年初。 公司 ...

Recursion Pharmaceuticals has been trying to rebuild momentum after a steep five year decline in shareholder returns, yet its ...

Chris Gibson, PhD, Recursion’s co-founder and CEO, discusses exclusively with GEN Edge his company’s ambitious plans to develop 100 pipeline candidates in roughly a decade, the savings in money and ...

These aren't for the faint of heart.

AI drug pioneer Recursion Pharmaceuticals said Wednesday that one of its experimental treatments hit a key milestone. Recursion was able to use its artificial intelligence-enabled drug discovery ...

Recursion Pharmaceuticals, a drug discovery company that applies artificial intelligence to biology, is shoring up its technology platform by buying two startups that bolster its chemistry ...